Given that sodium-glucose cotransporter 2 (SGLT-2) inhibitors exert beneficial effects on body fluid compartment distribution and volume status (mainly with regard to extracellular water, body fat mass, and visceral fat) without the loss of skeletal muscle mass [36], it would be of interest to determine whether combining an SGLT-2 inhibitor with low-dose furosemide in patients with CKD and fluid overload is an effective, safe way of achieving euvolemia. This evidence concerns the gene SLC5A2 and chronic kidney disease.